title: Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.
abstract: Heterologous prime/boost regimens are AIDS vaccine candidates because of their potential for inducing cellular immune responses. Here, we have developed a prime/boost regimen leading to rapid control of highly pathogenic immunodeficiency virus infection in macaques. The strategy, priming by an env and nef deletion-containing simian-human immunodeficiency virus (SHIV) proviral DNA followed by a single booster with a Gag-expressing Sendai virus (SeV-Gag), efficiently induced virus-specific T cells, which were maintained for more than 3 months until challenge. While all naive control macaques showed acute CD4(+) T-cell depletion at week 2 after an intravenous SHIV89.6PD challenge, all the macaques vaccinated with the prime/boost regimen were protected from depletion and showed greatly reduced peak viral loads compared with controls. Vaccination with the DNA alone or SeV-Gag alone was not enough to confer the consistent protection from the depletion, although it led to efficient secondary CD8(+) T-cell responses at week 2 after challenge. At week 1, a difference in the secondary responses between the protected and the unprotected macaques was clear; rapid augmentation of virus-specific CD8(+) T cells was detected in the former but not in the latter. Thus, our results indicate the importance of rapid secondary responses for reduction in the peak viral loads and protection from acute CD4(+) T-cell depletion.
authors.affiliation: AIDS Research Center, National Institute of Infectious Diseases, Musashi-murayama, Tokyo 208-0011, Japan. matano@nih.go.jp
authors.forename: T
authors.initials: T
authors.lastname: Matano
authors.forename: M
authors.initials: M
authors.lastname: Kano
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
authors.forename: A
authors.initials: A
authors.lastname: Takeda
authors.forename: Y
authors.initials: Y
authors.lastname: Nagai
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002678:Chimera; D005822:Genetic Vectors; D006678:HIV / Q000235:genetics / Q000502:physiology*; D016130:Immunophenotyping; D008212:Lymphocyte Depletion; D008251:Macaca; D029082:Sendai virus / Q000235:genetics*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000502:physiology*; D019444:Vaccines, DNA / Q000276:immunology*; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D015703:Antigens, CD; D019444:Vaccines, DNA